Salute e Benessere
Anaplastic Astrocytoma Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2025-2034) | DelveInsight
Discover the anaplastic astrocytoma new treatment @
Anaplastic astrocytoma is a malignant brain tumor primarily affecting adults aged 40 and above. The increasing prevalence of brain tumors, including anaplastic astrocytoma, is contributing to the expansion of the market. Anaplastic astrocytoma and glioblastoma multiforme are estimated to affect 5-8 people per 100,000 in the general population.
Currently, there is only one therapy approved for anaplastic astrocytoma, i.e., Merck's TEMODAR/TEMODAL. Merck initially commercialized TEMODAR/TEMODAL in various countries, while Baxter Oncology was responsible for manufacturing the TEMODAR injection.
The development of molecular diagnostics and advanced imaging techniques, such as MRI and PET scans, has improved early detection and accurate diagnosis of anaplastic astrocytoma. These advancements enable timely treatment interventions, thereby driving market growth.
The pipeline is limited to only a few drugs, including (Orbus Therapeutics), (Cothera Bioscience), (Jazz Pharmaceuticals/Chimerix), (Candel Therapeutics), and others.
Surgery remains the primary treatment for astrocytoma, allowing for both diagnosis and maximal safe tumor removal. Precision and safety are enhanced through advanced techniques, including neuronavigation, awake surgery, motor mapping, and the use of fluorescent dyes. Adjuvant treatments include steroids to reduce swelling, (an approved chemotherapy that damages DNA), radiation therapy, bevacizumab to limit tumor blood supply, tumor-treating fields (electric fields applied to the scalp), and antiseizure medications. Experimental approaches under investigation include targeted therapies, immunotherapy, and virus-based strategies designed to attack tumor cells selectively.
Currently, only a few companies are developing therapies specifically for anaplastic astrocytoma. Among them, is a key Phase III therapy being studied in combination with . The most recent update from , in September 2024 , reported that the STELLAR Phase III trial demonstrated a clinically meaningful improvement in Overall Survival (OS) and Progression-Free Survival (PFS) for patients with Grade 3 IDH-mutant astrocytoma who had progressed after radiation and adjuvant temozolomide, compared to lomustine alone. Since that update, there has been little new information on its development or regulatory progress. Furthermore, clinicaltrials.gov currently lists the trial as having an "Unknown status," creating uncertainty around its approval timeline.
Similarly, has completed Phase I/II trials; however, pipeline updates indicate no further trials are planned, adding to the uncertainty surrounding this therapy. Some emerging treatments, such as , are still in early-stage trials, with only a small number of patients with anaplastic astrocytoma included in basket studies. These developments underscore the ongoing need for therapies that specifically target anaplastic astrocytoma, highlighting challenges and opportunities in the future treatment landscape.
To know more about anaplastic astrocytoma treatment options, visit @
Some of the promising anaplastic astrocytoma drugs in clinical trials include (Orbus Therapeutics), (Cothera Bioscience), (Jazz Pharmaceuticals/Chimerix), (Candel Therapeutics), and others.
, also called α-difluoromethylornithine (DFMO), is a unique irreversible metabolic inhibitor that targets explicitly ODC. Its precise mechanism blocks the production of a critical enzyme involved in tumor growth in specific cancers. Unlike multi-targeted tyrosine kinase inhibitors currently available or under development, eflornithine acts on a single enzyme, ODC. The FDA first approved eflornithine in 1990 for the treatment of African trypanosomiasis, although it was never marketed in the U.S. In 2000, a topical formulation was approved for reducing unwanted facial hair in women, and in 2023, it received approval as maintenance therapy for high-risk neuroblastoma. In 2014, Orbus Therapeutics was granted Breakthrough Therapy Designation (BTD) for eflornithine in the treatment of anaplastic glioma.
is a potent oral CDK9 inhibitor capable of crossing the blood-brain barrier, where it downregulates short-lived, anti-apoptotic oncogene proteins such as Myc. It is being developed for high-grade glioma and diffuse intrinsic pontine glioma, both brain cancers associated with Myc overexpression. A Phase Ib clinical trial conducted by the U.S. National Cancer Institute (NCI) evaluated the safety and initial efficacy of zotiraciclib in combination with temozolomide in patients with recurrent high-grade glioma, including those with anaplastic astrocytoma. Currently, zotiraciclib is under evaluation in a Phase I/II trial for recurrent high-grade astrocytomas.
The anticipated launch of these emerging therapies are poised to transform the anaplastic astrocytoma market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the anaplastic astrocytoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about therapy for anaplastic astrocytoma @
Anaplastic astrocytoma is a rare and aggressive brain tumor that arises from astrocytes, star-shaped cells that, along with other similar cells, form the supportive tissue surrounding and protecting nerve cells in the brain and spinal cord. These supportive cells, known as glial cells, form what is referred to as glial tissue. Tumors originating from this tissue, including astrocytomas, are classified as gliomas. The symptoms of anaplastic astrocytoma vary depending on the tumor's size and location in the brain. The precise cause of this tumor is still unknown.
The anaplastic astrocytoma epidemiology section provides insights into the historical and current anaplastic astrocytoma patient pool and forecasted trends for the leading markets. In anaplastic astrocytoma, there is substantial dominance in men, with a man-to-woman incidence reported as . The frequency of IDH-wildtype is slightly more than IDH-mutant in anaplastic astrocytomas.
The anaplastic astrocytoma market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:
Download the report to understand which factors are driving the anaplastic astrocytoma therapeutics market trends @
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key anaplastic astrocytoma companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key astrocytoma companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key astrocytoma companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key glioma companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/anaplastic-astrocytoma-market-is-predicted-to-exhibit-remarkable-growth-during-the-forecast-period-20252034--delveinsight-302582787.html